The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left"> Patient with BMD at baseline visit</td><td align="center">58.8% (87/148)</td></tr><tr><td align="left">Patient with BMD at any followup visit</td><td align="center">20.3% (30/148)</td></tr><tr><td align="left">Vitamin D supplementation during followup</td><td align="center">36.9% (55/149)</td></tr><tr><td align="left">Calcium supplementation during followup</td><td align="center">35.6% (53/149)</td></tr><tr><td align="left">Bisphosphonate use during followup</td><td align="center">12.7% (18/142)</td></tr><tr><td align="left">Calcitonin use during followup</td><td align="center">0% (0/148)</td></tr><tr><td align="left">Either a repeat BMD or treatment with a bisphosphonate during followup</td><td align="center">28.4% (42/148)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Evaluations screening strategies, prevention measures, and pharmacological treatment of osteoporosis. 

Journal of Oncology

tab2

Table 2

Table 2: The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer 

Table 2 | The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer 